AR035330A1 - Uso de metabolito de (-) -cis-6-fenil-5- (4-(2-pirrolidin-1-iletoxi) fenil)-5, 6, 7, 8-tetrahidronaftalen-2-ol, metabolitos y composiciones que los contienen - Google Patents
Uso de metabolito de (-) -cis-6-fenil-5- (4-(2-pirrolidin-1-iletoxi) fenil)-5, 6, 7, 8-tetrahidronaftalen-2-ol, metabolitos y composiciones que los contienenInfo
- Publication number
- AR035330A1 AR035330A1 ARP010101626A ARP010101626A AR035330A1 AR 035330 A1 AR035330 A1 AR 035330A1 AR P010101626 A ARP010101626 A AR P010101626A AR P010101626 A ARP010101626 A AR P010101626A AR 035330 A1 AR035330 A1 AR 035330A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenyl
- disease
- cancer
- formula
- metabolite
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Abstract
Uso de un metabolito de (-)-cis-6-fenil-5-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-2-ol de la fórmula (1) para la preparación de medicamentos caracterizado porque es para el tratamiento de osteoporosis, cáncer de mama, hiperlipidemia, arteriosclerosis, enfermedad de Alzheimer, cataratas, pérdida de libido, disfunción sexual masculina, cáncer de colon, verrugas dérmicas, enfermedad autoinmune, alopecia, acné, enfermedad cardiovascular, diabetes, endometriosis, disfunción sexual femenina, hiperglucemia, obesidad, trastorno obsesivo compulsivo, síndrome premenstrual, carcinoma prostático, hiperplasia prostática benigna, hipertensión pulmonar, dano por reperfusión, artritis reumatoide, osteoartritis, seborrea, ginecomastia senil, deficiencia de testosterona, síndrome de Turner, fibrosis uterina, vaginitis atrófica, incontinencia, cáncer de útero, hirsutismo, bulimia, anorexia, deseo sexual hipoactivo, trastorno de la excitación sexual, dispareunia, vaginismo, prolapso, infecciones del tracto urinario, apoplejía, infarto de miocardio, insuficiencia renal aguda o crónica, enfermedad oclusiva arterial periférica, fenómeno de Raynaud, cánceres de ovario, hígado y práncreas, así como de cáncer desmoide, glioma y carcinoma de células renales, o promover la curación de heridas, incrementar la frecuencia de los orgasmos o reducción del pH vaginal, fórmula (1), donde R1 se selecciona de fórmulas (2), (3) y (4) o -NH(CH2)3COR6; R5 se selecciona de H o CH3; R2, R3, R4 y R7 son iguales o diferentes y se seleccionan de H y OR5; y R6 se selecciona de -OH - -NHCH2COOH, siempre que: (a) si R1 es fórmula (2) o -NH(CH2)3COOH y (b) R2 es OH u OCH3 y R3 y R7 son H, o si R1 es como se definió (a) anteriormente, y (c) R2 y R7 son H y R3 es OH u OCH3, entonces R4 no es H o un isómero óptico, estereoisómero, regioisómero o isómero configuracional o isómero geométrico de éste o un tautómero o una sal farmacéuticamente aceptable de éste. Estos compuestos de la presente se pueden utilizar como patrones en ensayos analíticos o como intermedio para la síntesis química o biosíntesis posterior de entidades químicas. La presente se refiere también a composiciones farmacéuticas para el tratamiento de enfermedades y a su uso en la preparación de las mismas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26719800P | 2000-04-07 | 2000-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035330A1 true AR035330A1 (es) | 2004-05-12 |
Family
ID=23017734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010101626A AR035330A1 (es) | 2000-04-07 | 2001-04-05 | Uso de metabolito de (-) -cis-6-fenil-5- (4-(2-pirrolidin-1-iletoxi) fenil)-5, 6, 7, 8-tetrahidronaftalen-2-ol, metabolitos y composiciones que los contienen |
Country Status (38)
Country | Link |
---|---|
US (2) | US6455572B1 (es) |
EP (1) | EP1268453B1 (es) |
JP (1) | JP2004510693A (es) |
KR (1) | KR20020089434A (es) |
CN (1) | CN1209353C (es) |
AP (1) | AP2002002641A0 (es) |
AR (1) | AR035330A1 (es) |
AT (1) | ATE333450T1 (es) |
AU (2) | AU2001240985B2 (es) |
BG (1) | BG107137A (es) |
BR (1) | BR0109838A (es) |
CA (1) | CA2405070A1 (es) |
CR (1) | CR6766A (es) |
CZ (1) | CZ20023223A3 (es) |
DE (1) | DE60121557T2 (es) |
DK (1) | DK1268453T3 (es) |
EA (1) | EA004866B1 (es) |
EE (1) | EE200200580A (es) |
ES (1) | ES2266169T3 (es) |
HK (1) | HK1052511B (es) |
HR (1) | HRP20020802A2 (es) |
HU (1) | HUP0300419A3 (es) |
IL (1) | IL152082A0 (es) |
IS (1) | IS6549A (es) |
MA (1) | MA26890A1 (es) |
MX (1) | MXPA02009940A (es) |
NO (1) | NO20024767L (es) |
OA (1) | OA12325A (es) |
PA (1) | PA8514901A1 (es) |
PE (1) | PE20011183A1 (es) |
PL (1) | PL358593A1 (es) |
PT (1) | PT1268453E (es) |
SK (1) | SK14092002A3 (es) |
TN (1) | TNSN01052A1 (es) |
TR (1) | TR200202310T2 (es) |
UY (1) | UY26656A1 (es) |
WO (1) | WO2001077093A1 (es) |
ZA (1) | ZA200207995B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US7001926B2 (en) | 2000-03-10 | 2006-02-21 | Oxigene, Inc. | Tubulin binding agents and corresponding prodrug constructs |
US7091240B2 (en) | 2000-03-10 | 2006-08-15 | Oxigene, Inc. | Tubulin binding ligands and corresponding prodrug constructs |
CZ20002567A3 (cs) * | 2000-07-11 | 2001-12-12 | Léčiva, A.S. | Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby |
EP1192945A3 (en) * | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
US7479504B2 (en) * | 2002-01-18 | 2009-01-20 | Merck & Co., Inc. | Edg receptor agonists |
AU2003208516A1 (en) * | 2002-03-14 | 2003-09-22 | Warner-Lambert Company Llc | Method for characterizing metabolites using hydrogen/deuterium exchange |
US20050095241A1 (en) * | 2003-08-26 | 2005-05-05 | Vadlamudi Ratna K. | Estrogen receptor modulators and uses thereof |
US7456214B2 (en) | 2004-05-03 | 2008-11-25 | Baylor University | Chromene-containing compounds with anti-tubulin and vascular targeting activity |
AU2012200714B2 (en) * | 2004-08-13 | 2014-04-17 | Wyeth Llc | Tanaproget derivatives, metabolites, and uses thereof |
PT1778710E (pt) * | 2004-08-13 | 2012-04-12 | Wyeth Llc | Derivados de tanaproget, metabolitos e suas utilizações |
WO2006136944A1 (en) * | 2005-06-22 | 2006-12-28 | Pfizer Products Inc. | Stereoselective hydrogenation process for preparing cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-methoxy-5,6,7,8-tetrahydronaphthalene hydrochloride |
US7902147B2 (en) | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
TW201043595A (en) * | 2009-03-13 | 2010-12-16 | Organon Nv | Tetrahydronaphthalen-2-ol derivatives |
US9845291B2 (en) | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3522319A (en) * | 1964-01-23 | 1970-07-28 | Ciba Geigy Corp | Phenol substituted tetrahydronaphthalenes useful as estrogenics |
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
UA51676C2 (uk) | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
TW442286B (en) | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
-
2001
- 2001-03-19 DK DK01912069T patent/DK1268453T3/da active
- 2001-03-19 AU AU2001240985A patent/AU2001240985B2/en not_active Ceased
- 2001-03-19 KR KR1020027013379A patent/KR20020089434A/ko active Search and Examination
- 2001-03-19 CA CA002405070A patent/CA2405070A1/en not_active Abandoned
- 2001-03-19 PL PL01358593A patent/PL358593A1/xx not_active Application Discontinuation
- 2001-03-19 EE EEP200200580A patent/EE200200580A/xx unknown
- 2001-03-19 AT AT01912069T patent/ATE333450T1/de not_active IP Right Cessation
- 2001-03-19 BR BR0109838-1A patent/BR0109838A/pt not_active IP Right Cessation
- 2001-03-19 SK SK1409-2002A patent/SK14092002A3/sk unknown
- 2001-03-19 WO PCT/IB2001/000427 patent/WO2001077093A1/en active IP Right Grant
- 2001-03-19 AU AU4098501A patent/AU4098501A/xx active Pending
- 2001-03-19 CZ CZ20023223A patent/CZ20023223A3/cs unknown
- 2001-03-19 HU HU0300419A patent/HUP0300419A3/hu unknown
- 2001-03-19 JP JP2001575567A patent/JP2004510693A/ja not_active Withdrawn
- 2001-03-19 PT PT01912069T patent/PT1268453E/pt unknown
- 2001-03-19 CN CNB018077935A patent/CN1209353C/zh not_active Expired - Fee Related
- 2001-03-19 EA EA200200949A patent/EA004866B1/ru not_active IP Right Cessation
- 2001-03-19 EP EP01912069A patent/EP1268453B1/en not_active Expired - Lifetime
- 2001-03-19 MX MXPA02009940A patent/MXPA02009940A/es active IP Right Grant
- 2001-03-19 AP APAP/P/2002/002641A patent/AP2002002641A0/en unknown
- 2001-03-19 TR TR2002/02310T patent/TR200202310T2/xx unknown
- 2001-03-19 OA OA1200200305A patent/OA12325A/en unknown
- 2001-03-19 ES ES01912069T patent/ES2266169T3/es not_active Expired - Lifetime
- 2001-03-19 DE DE60121557T patent/DE60121557T2/de not_active Expired - Fee Related
- 2001-03-19 IL IL15208201A patent/IL152082A0/xx unknown
- 2001-04-04 US US09/825,980 patent/US6455572B1/en not_active Ceased
- 2001-04-05 PE PE2001000320A patent/PE20011183A1/es not_active Application Discontinuation
- 2001-04-05 UY UY26656A patent/UY26656A1/es not_active Application Discontinuation
- 2001-04-05 AR ARP010101626A patent/AR035330A1/es unknown
- 2001-04-06 TN TNTNSN01052A patent/TNSN01052A1/fr unknown
- 2001-04-09 PA PA20018514901A patent/PA8514901A1/es unknown
-
2002
- 2002-09-17 IS IS6549A patent/IS6549A/is unknown
- 2002-09-23 BG BG107137A patent/BG107137A/bg unknown
- 2002-10-02 MA MA26847A patent/MA26890A1/fr unknown
- 2002-10-02 CR CR6766A patent/CR6766A/es not_active Application Discontinuation
- 2002-10-03 NO NO20024767A patent/NO20024767L/no not_active Application Discontinuation
- 2002-10-04 ZA ZA200207995A patent/ZA200207995B/en unknown
- 2002-10-07 HR HR20020802A patent/HRP20020802A2/hr not_active Application Discontinuation
-
2003
- 2003-05-30 US US10/448,751 patent/USRE39419E1/en not_active Expired - Fee Related
- 2003-07-08 HK HK03104866.0A patent/HK1052511B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035330A1 (es) | Uso de metabolito de (-) -cis-6-fenil-5- (4-(2-pirrolidin-1-iletoxi) fenil)-5, 6, 7, 8-tetrahidronaftalen-2-ol, metabolitos y composiciones que los contienen | |
JP7038712B2 (ja) | ブルトン型チロシンキナーゼ(btk)阻害剤のe3リガーゼリガンドとのコンジュゲーションによるbtkの分解および使用法 | |
AU762735B2 (en) | Nonsteroidal antiinflammatories | |
Li et al. | Improved synthesis of 2, 2′-arylmethylene bis (3-hydroxy-5, 5-dimethyl-2-cyclohexene-1-one) derivatives catalyzed by urea under ultrasound | |
MX2015002697A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b. | |
JP2016531121A (ja) | 疾患の治療のためのkdm1a阻害剤 | |
RU2009142434A (ru) | Производные триазолопиридин-карбоксамидов и триазолопиримидин-карбоксамидов, их получение и их применение в терапии | |
EP3328831A1 (en) | A method for preparing methyl (z)-3-[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene)-oxindole-6-carboxylate (intedanib, nintedanib) | |
JP2020528877A (ja) | 新規化合物及びそれを有効成分として含有する、線維症または非アルコール性脂肪肝炎の予防、改善または治療用組成物 | |
Zhang et al. | Synthesis and cytotoxic studies of novel 5-phenylisatin derivatives and their anti-migration and anti-angiogenic evaluation | |
JP2015504917A (ja) | Mogat−2阻害剤として有用な新規モルホリニル誘導体 | |
Zhou et al. | Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer | |
CA2603866A1 (en) | Androgen modulators | |
Feng et al. | The novel synthetic triterpene methyl 3β-O-[4-(2-Aminoethylamino)-4-oxo-butyryl] olean-12-ene-28-oate inhibits breast tumor cell growth in vitro and in vivo | |
Alizadeh et al. | Solvent-free synthesis of penta-substituted pyrroles: one-pot reaction of amine, alkyl acetoacetate, and fumaryl chloride | |
AU2016426847A1 (en) | Method for preparing deuterated imidazole diketone compound | |
FR2712289A1 (fr) | Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent. | |
CN101371832A (zh) | 三乙酰穿心莲内酯作为炎性细胞因子抑制剂的医药用途 | |
IE900572L (en) | Hydroxyalkane carboxylic acid derivatives, their production¹and use | |
JP2007099640A (ja) | 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物 | |
EA201390615A1 (ru) | Производные дитерпеноидов, обладающие биологическими свойствами | |
JP2004509899A (ja) | トリアゾロ−エポチロン | |
JP2016500649A5 (es) | ||
JPH10330254A (ja) | 翼状片の進行および術後の再発抑制剤 | |
CN110437119B (zh) | 一种n-取代含氮杂环衍生物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |